How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,040 results for

Intravenous Drug Abuse

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients

or intolerance to iron isomaltoside or other parenteral iron preparations Intravenous iron supplement within 6 months prior to inclusion On oral iron substitution (unless the subject agrees to stop treatment prior to randomisation) Ongoing rejections or infections Alcohol or drug abuse within 3 months of informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance with study procedures or study drug intake Intake of an investigational drug in another (...) and quality of life in iron-deficient heart transplant recipients Condition or disease Intervention/treatment Phase Heart Transplant Recipients Drug: Iron Isomaltoside 1000 Other: Placebo: NaCl 0,9% Phase 2 Phase 3 Detailed Description: Iron deficiency is prevalent in patients with heart failure. Iron deficiency is associated with a worse prognosis, and randomised controlled trials have shown that correction of iron deficiency with intravenous iron therapy improves functional capacity, quality of life

2018 Clinical Trials

102. Narcotic Free TIVA (Total Intravenous Anesthesia) and the Incidence of Unacceptable Movements Under General Anesthesia During ACDF (Anterior Cervical Discectomy and Fusion) Surgery

in the postoperative period. Condition or disease Intervention/treatment Phase Anterior Cervical Discectomy and Fusion (ACDF) Drug: Remifentanil Drug: Ketamine Drug: Dexmedetomidine Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 80 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment Official Title: The Effect of a Narcotic Free Total Intravenous (...) Narcotic Free TIVA (Total Intravenous Anesthesia) and the Incidence of Unacceptable Movements Under General Anesthesia During ACDF (Anterior Cervical Discectomy and Fusion) Surgery Narcotic Free TIVA (Total Intravenous Anesthesia) and the Incidence of Unacceptable Movements Under General Anesthesia During ACDF (Anterior Cervical Discectomy and Fusion) Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results

2018 Clinical Trials

103. Liver Function After Intravenous Methylprednisolone Administration

topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: moderate-to-severe Graves Orbitopathy active, moderate-to-severe Graves Orbitopathy according to EUGOGO. Drug: every week IVMP therapy 12 pulses of intravenous methylprednisolone (IVMP) in every week schedule (for the first 6 weeks 0.5g IVMP per week, for the next 6 weeks 0.25g IVMP per week; cumulative dose 4.5g) according to EUGOGO recommendations Active Comparator: Dysthyroid Orbit Neuropathy (...) Dysthyroid Orbit Neuropathy according to EUGOGO Drug: very high doses IVMP therapy 3 pulses of intravenous methylprednisolone (IVMP) (1.0g/day for 3 consecutive days; cumulative dose 3.0g) according to EUGOGO recommendations Outcome Measures Go to Primary Outcome Measures : Influence of IVMP pulses in 12 every week schedule on mean ALT [ Time Frame: 12 weeks ] Administration of IVMP in 12 every week schedule: 6 weeks 0.5g IVMP per week plus 6 weeks 0.25g IVMP per week. Change of mean value of alanine

2018 Clinical Trials

104. Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously to Healthy Adults

significant medical condition that in the opinion of investigator would jeopardize the safety or rights of the subject including (but not limited to): diabetes mellitus type I, chronic hepatitis; OR clinically significant forms of drug or alcohol abuse, asthma, autoimmune disease, psychiatric disorders, heart disease, or cancer. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using (...) Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously to Healthy Adults Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously to Healthy Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved

2018 Clinical Trials

105. Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults

), and/or surgery that would result in the subject's inability to absorb or metabolize the study drug (eg, gastrectomy, gastric bypass, cholecystectomy). Participant has a history of any drug or alcohol abuse in the past 2 years, or alcohol consumption greater than 21 units per week in males and 14 units per week in females. A unit of alcohol is equivalent to 1 can of beer, 1 glass of wine, or the equivalent of 1 alcoholic drink. Alcohol consumption will be prohibited within 96 hours before Check-in on Day -1 (...) Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2018 Clinical Trials

106. Evaluation of Second Esmarch Application on Intravenous Regional Anesthesia Effectiveness

for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 80 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Male and female patients aged 18-100 who need short upper extremity or hand surgery (cases lasting less than 45 minutes) in the outpatient setting will be considered for the study. Exclusion criteria: patients requesting to withdraw from the study and patients with a history of drug abuse or illicitly used (...) controlled drugs or substances within the last year. The study population will be divided into two groups: one group receiving the standard IVRA procedure and one group receiving the modified IVRA procedure (which simply includes the reapplication of the Esmarch bandage after the local anesthetic is administered intravenously). Due to limited information from other intravenous regional anesthesia studies, at least 40 subjects in each group will be needed (at least 80 patients total). Any patient who

2018 Clinical Trials

107. A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6

-348 and will be confined to the CRU until at least Day 8. If participants are not eligible for discharge on Day 8, they may remain in the CRU up to Day 11. Radiolabelled analytes of AG-348 will be administered in a single oral and intravenous (IV) dose on Day 1. Participants will be required to fast pre-dose, remain in a supine position for 1 hour post-dose and avoid water for 2 hours post-dose. Condition or disease Intervention/treatment Phase Healthy Volunteers Drug: AG-348 Drug: [13C6]AG-348 (...) and Concomitant Single Intravenous Microdose of [13C6]AG-348 Actual Study Start Date : May 24, 2018 Actual Primary Completion Date : June 1, 2018 Actual Study Completion Date : June 4, 2018 Arms and Interventions Go to Arm Intervention/treatment Experimental: AG-348 On Day 1, participants fasting for at least 10 hours the night before will receive oral AG-348 followed by intravenous (IV) [13C6]AG-348, 1 hour post-oral dose. Drug: AG-348 120 milligrams (mg) oral capsule, single dose, contains 100 microcuries

2018 Clinical Trials

108. A Study of Intravenous Perampanel in Japanese Participants With Epilepsy

of marketed antiepileptic drugs (AED[s]). No change of dosing regimen for concomitant AED(s) is planned during the intravenous Treatment and Follow-up Phases. Considered reliable and willing to be available for the study period by the investigator, and are able to record seizures and report adverse events (AEs) by themselves or have a caregiver who can record seizures and report AEs for them. Exclusion Criteria: A history of drug or alcohol dependency or abuse. A history of status epilepticus. Unsuitable (...) . Condition or disease Intervention/treatment Phase Epilepsy Seizures Drug: Perampanel Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 20 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Multicenter, Uncontrolled, Open-label Study to Evaluate the Safety and Tolerability of Intravenous Perampanel as Substitute for Oral Tablet in Subjects

2018 Clinical Trials

109. Bolus Administration of Intravenous Lidocaine at the Time of Abdominal Hysterectomy

Hysterectomy Drug: lidocaine Drug: Placebo Not Applicable Detailed Description: Total abdominal hysterectomy (TAH) is the most common gynecological operation worldwide. Some studies noticed about abused of opioids in postoperative care, led to a more adverse effect of opioids, slow recovery, prolong the length of hospitalized stay and consequently increase the unnecessary cost of treatment. Guidelines have considered using preoperative analgesics for reducing post-operative opioids consumption, including (...) Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: lidocaine A bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia. Drug: lidocaine a bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia. Other Name: Experimental Placebo Comparator: Placebo A bolus intravenous dose of a saline placebo

2018 Clinical Trials

110. A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

of intraperitoneal and intravenous paclitaxel plus apatinib and S-1 in the conversion therapy of gastric cancer with positive exfoliative cancer cells Condition or disease Intervention/treatment Phase Gastric Cancer With Positive Exfoliative Cancer Cells Drug: apatinib Drug: paclitaxel Drug: S-1 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 36 participants Intervention Model: Single Group Assignment Masking: None (Open Label (...) Experimental: paclitaxel,apatinib and S-1 Drug: apatinib apatinib:500mg qd po, 28 days is a cycle. preoperative 2 cycles, 2 cycles after surgery. Drug: paclitaxel Paclitaxel: intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 ,21 days is a cycle. preoperative 3 cycles, 3 cycles after surgery. Drug: S-1 S-1: According to the body surface area, BSA <1.25m2,40mg bid; 1.25m2≤BSA≤1.5m2,50mg bid; BSA >1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend

2018 Clinical Trials

111. A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

study designed to evaluate the safety and PK of intravenously administered superoxide dismutase mimetic GC4711 in healthy volunteers. Condition or disease Intervention/treatment Phase Healthy Drug: GC4711 30mg Drug: GC4711 60mg Drug: GC4711 90mg Drug: GC4711 120mg Drug: Placebo Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 40 participants Allocation: Randomized Intervention Model: Sequential Assignment Masking (...) Intervention/treatment Experimental: GC4711 30mg Drug: GC4711 30mg single dose given via a 15 minute intravenous infusion Experimental: GC4711 60mg Drug: GC4711 60mg single dose given via a 15 minute intravenous infusion Experimental: GC4711 90mg Drug: GC4711 90mg single dose given via a 15 minute intravenous infusion Experimental: GC4711 120mg Drug: GC4711 120mg single dose given via a 15 minute intravenous infusion Placebo Comparator: Placebo Drug: Placebo single dose of normal saline given via a 15

2018 Clinical Trials

112. Acute Forefoot Phlegmon – A Complication of Intravenous Heroin-Addiction (PubMed)

with pain and swelling of the left forefoot but not any recent trauma. Microbiology identified streptococci. The medical history was positive for intravenous heroin abuse. The diagnosis of forefoot phlegm due to drug addition was confirmed. Treatment was realised by a combination of intravenous antibiosis and drainage. Intravenous drug addiction is a significant risk factor for SSTI. (...) Acute Forefoot Phlegmon – A Complication of Intravenous Heroin-Addiction Infections of the skin and soft tissues (SSTI) are clinical entities with variable presentations, causes, and levels of clinical severity. They are frequent in emergency departments. The most common pathogen in the Western World is Staphylococcus aureus. SSTI may provide a hint to underlying pathologies such as diabetes and other states of immune compromise. Here we present a 41-year-old non-diabetic male patient

Full Text available with Trip Pro

2018 Open access Macedonian journal of medical sciences

113. Hospitalizations related to opioid abuse/dependence and associated serious infections from 2002 to 2012 (PubMed)

Hospitalizations related to opioid abuse/dependence and associated serious infections from 2002 to 2012 Serious infection is a recognized complication of intravenous drug abuse and a major cause of morbidity and mortality among intravenous drug users. Trends in rates of serious infection and the associated costs related to opioid abuse/dependence have not been previously investigated in the context of the US opioid use epidemic. Our study, using a nationally representative sample of US (...) inpatient hospitalizations, showed that hospitalizations related to opioid abuse/dependence both with and without associated serious infection significantly increased from 2002 to 2012, respectively, from 301,707 to 520,275 and from 3,421 to 6,535. Additionally, inpatient charges for both types of hospitalizations almost quadrupled over the same time period, reaching almost $15 billion for hospitalizations related to opioid abuse/dependence and more than $700 million for those related to associated

Full Text available with Trip Pro

2016 Health affairs (Project Hope)

114. Drug Interventions for Chronic Non-Cancer Pain

, Buchser E, Burton A, Caraway D, et al. Polyanalgesic Consensus Conference--2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation. 2012 Sep;15(5):467-82. PubMed: PM22849581 Drug Interventions for Chronic Non-Cancer Pain 2 8. Mailis A, Taenzer P. Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks. Pain Res Manag. 2012 (...) Drug Interventions for Chronic Non-Cancer Pain TITLE: Drug Interventions for Chronic Non-Cancer Pain: Guidelines and Recommendations DATE: 05 February 2014 RESEARCH QUESTION What are the evidence-based guidelines regarding drug interventions for chronic non-cancer pain? KEY MESSAGE One systematic review of guidelines and eight evidence-based guidelines were identified regarding drug interventions for chronic non-cancer pain. METHODS A limited literature search was conducted on key resources

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

115. Endocarditis due to a co-infection of Candida albicans and Candida tropicalis in a drug abuser. (PubMed)

Endocarditis due to a co-infection of Candida albicans and Candida tropicalis in a drug abuser. In recent decades the incidence of Candida endocarditis has increased dramatically. Despite the application of surgery and antifungal therapy, Candida endocarditis remains a life-threatening infection with significant morbidity and mortality. We report a 37-year-old male drug abuser presenting with high fever, chest pain, loss of appetite and cardiac failure. His echocardiography revealed mobile (...) large tricuspid valve vegetations. Fungal endocarditis was confirmed by culturing of the resected vegetation showing mixed growth of Candida albicans and Candida tropicalis, although three consecutive blood cultures were negative for Candida species. Phenotypic identification was reconfirmed by sequencing of the internal transcribed spacer (ITS rDNA) region. The patient was initially treated with intravenous fluconazole (6 mg kg(-1) per day), followed by 2 weeks of intravenous amphotericin B

Full Text available with Trip Pro

2013 Journal of Medical Microbiology

116. Intravenous Ketamine and Postoperative Pain Following Cesarean Section.

: January 12, 2017 Sponsor: Assiut University Information provided by (Responsible Party): Abdelrady S Ibrahim, MD, Assiut University Study Details Study Description Go to Brief Summary: The purpose of this study is to investigate the analgesic effect of low-dose intravenous ketamine in pregnant mothers undergoing cesarean section under Bupivacaine spinal anesthesia. Condition or disease Intervention/treatment Phase Postoperative Pain Drug: Ketamine Other: Normal saline Phase 2 Detailed Description (...) Cesarean Section Under Spinal Anesthesia: A Randomized Control Clinical Trial. Study Start Date : January 2017 Estimated Primary Completion Date : June 2017 Estimated Study Completion Date : October 2017 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Ketamine group will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes. Drug: Ketamine

2017 Clinical Trials

117. Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease

or placebo via intravenous infusion This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 124 weeks. Participants will make multiple visits to the clinic and will be contacted by telephone 6 months after last dose of study drug for a follow-up assessment. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 0 participants Allocation: Randomized Intervention Model: Parallel Assignment (...) by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Vedolizumab IV 300 mg Q4W Vedolizumab 300 mg, intravenous (IV), once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 4 weeks (Q4W) starting from Week 6 to Week 102. Drug: Vedolizumab Vedolizumab intravenous infusion Other Names: MLN0002 ENTYVIO KYNTELES Experimental: Vedolizumab IV 300 mg Q8W + Placebo Vedolizumab 300 mg, IV, once at Day 1

2017 Clinical Trials

118. Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu®) Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support

Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: VIS410 low dose Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir Drug: Low dose of VIS410 in addition to oseltamivir Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir Experimental: VIS410 high dose Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir Drug: High dose of VIS410 (...) in addition to oseltamivir Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir Placebo Comparator: Placebo Single intravenous infusion of placebo in addition to oseltamivir Drug: Placebo in addition to oseltamivir Single intravenous infusion of placebo in addition to oseltamivir Outcome Measures Go to Primary Outcome Measures : Evaluate the effect of 2 dose levels of VIS410 + oseltamivir on clinical outcome as assessed by comparison of clinical status ordinal Day 7 scores

2017 Clinical Trials

119. VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523lS), Administered Intravenously or Subcutaneously to Healthy Adults

participation. Receipt of any investigational study agent within 28 days prior to enrollment. Any other chronic or clinically significant medical condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer, including but not limited to: diabetes mellitus type I, chronic hepatitis; OR clinically significant forms of: drug or alcohol abuse, asthma, autoimmune disease, psychiatric disorders, heart disease, or cancer. Contacts and Locations Go to Information from (...) VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523lS), Administered Intravenously or Subcutaneously to Healthy Adults VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523lS), Administered Intravenously or Subcutaneously to Healthy Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms

2017 Clinical Trials

120. A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects

by (Responsible Party): Eisai Inc. ( EA Pharma Co., Ltd. ) Study Details Study Description Go to Brief Summary: The study (E3112/CP1) is a single-center, randomized, double-blind, placebo-controlled, single intravenous ascending dose study conducted in Japanese healthy adult males to evaluate the pharmacokinetics (PK), safety, and immunogenicity of E3112 following a single intravenous dose of E3112. Condition or disease Intervention/treatment Phase Healthy Male Volunteers Drug: Placebo Drug: E3112 Early Phase (...) 25, 2017 Actual Primary Completion Date : June 12, 2017 Actual Study Completion Date : November 22, 2017 Arms and Interventions Go to Arm Intervention/treatment Placebo Comparator: Cohort 1: Placebo Intravenous placebo infusion Drug: Placebo Intravenous infusion Experimental: Cohort 1: E3112 Intravenous E3112 infusion Drug: E3112 Intravenous infusion Placebo Comparator: Cohort 2: Placebo Intravenous placebo infusion Drug: Placebo Intravenous infusion Experimental: Cohort 2: E3112 Intravenous

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>